Vanda Pharmaceuticals (VNDA) earnings call transcripts

Management framed 2026 as an investment-heavy transition year, with launches and trial readouts nearing completion and expenses expected to moderate afterward.

Management framed 2026 as a growth and diversification year, emphasizing expanding commercial reach while acknowledging early launch uncertainty and slower study recruitment.

Management framed 2025 as a commercial-growth year while highlighting a broad pipeline, but stressed that new launches contribute little to near-term guidance.